In a Society of Actuaries article, RGA's Ryan Holt illustrates the calculation of mortality impact with audit data ...

Although several per- and polyfluoroalkyl substances (PFAS) have been banned or limited in their future use, they continue to have a lasting impact on the environment and human health, with detectable levels apparent in most individuals.

This article from Seeing Beyond Risk discusses how life insurers can navigat...

It is never easy or enjoyable to deliver bad news to a customer. In an article that first appeared in the Claims Journal, explore new strategies in...

In this Inside RGA interview, Natalie Ho discusses RGA’s refreshed brand, including the inspiration behind its key visual elements.

In an aging world, understanding and responding to a growing retirement protection gap is not just an economic and societal imperative; it's a significant opportunity for life insurers. RGA’s David Lipovics offers lessons learned from the success of pension risk tran...

This article delves into the theme of World Food Day 2023, exploring how water can impact human health, as well as the effects of climate change and environment factors on the accessibility of clean and safe water.

As discoveries within the field of genetics grow exponentially, the field's importance to insurance medicine continues to grow. In this Inside RGA interview, RGA Consultant Geneticist Dr. Sajel L. Kana, MD, FAAP, FACMG, describes her commitment to genetics a...

Responding to customer demands for action on climate change, insurers are exploring “green insurance” products and approaches that raise awareness around sustainability and directly support green initiatives.

This article from Longevity Bulletin provides an overview of mortality modeling under the survival analysis framework, machine learning methods, ext...

This is the second article of a four-part series that will also include an overview and articles exploring the survey’s impl...

In this article from On the Risk, Dr. Lauren Garfield explores the increased use of GLP-1 receptor agonist drugs to combat obesity and the potential impact on underwriting.